Try our Advanced Search for more refined results

Ariosa Diagnostics, Inc v. Sequenom, Inc.

  1. June 27, 2016

    High Court Won't Hear Patent Row Over Fetal DNA Test

    The U.S. Supreme Court has declined to hear Sequenom Inc.'s appeal of a decision invalidating its patent for a fetal DNA test, after lower courts found the patent ineligible because it's directed toward a natural phenomenon, according to an order list Monday.

  2. December 24, 2015

    Patent Cases To Watch In 2016

    The courts are set to hear cases next year that could clear the way for bigger damages in patent cases, provide guidance on patent-eligibility following recent U.S. Supreme Court rulings, and result in more findings of patent exhaustion. Here are some of the cases patent attorneys will be watching in 2016.

  3. December 02, 2015

    Full Fed. Circ. Won't Rehear Fetal DNA Patent Row

    The Federal Circuit on Wednesday denied a request to rehear en banc a decision that Sequenom Inc.'s patent for a fetal DNA test is patent-ineligible because it is directed to a natural phenomenon, based on the framework established by the U.S. Supreme Court's Myriad and Mayo decisions.

  4. October 20, 2015

    Sequenom's 'Sky Is Falling' Claims Blasted In DNA Patent Row

    Sequenom Inc. should not get a crack at overturning a recent Federal Circuit affirmation that its patent for a fetal DNA test is patent-ineligible, two companies facing infringement allegations argued Monday, citing Sequenom's "sky is falling!" rhetoric and U.S. Supreme Court precedent.

  5. August 31, 2015

    Full Fed. Circ. Urged To Review Axing Of DNA Test Patent

    Major industry groups, professors and corporations filed a raft of amicus briefs last week urging the full Federal Circuit to rehear a decision that Sequenom Inc.'s fetal DNA test patent is invalid because it involves natural material.

  6. August 14, 2015

    Fed. Circ. Urged To Review Toss Of Fetal DNA Test Patent

    The Federal Circuit's recent determination that Sequenom Inc.'s fetal DNA test patent is invalid because it involves natural material poses an "existential threat" to patent production in multiple fields of invention, the company argued on Thursday.

  7. June 15, 2015

    Even Breakthrough Patents Can Be Invalid, Sequenom Shows

    The Federal Circuit's decision Friday that Sequenom Inc.'s patent for prenatal DNA tests is invalid for claiming a natural phenomenon makes clear that many medical and biotechnology patents are at risk from the U.S. Supreme Court's Mayo and Myriad rulings, even those involving groundbreaking innovations, attorneys say.

  8. June 12, 2015

    Fed. Circ. Nixes Fetal DNA Test Patent Under Myriad, Mayo

    The Federal Circuit on Friday affirmed a ruling that Sequenom Inc.'s patent for prenatal DNA tests used to determine the gender of a fetus is not patent-eligible because it is directed to a natural phenomenon, citing the framework established by the U.S. Supreme Court's Myriad and Mayo decisions.